0.78Open0.78Pre Close0 Volume1 Open Interest1.00Strike Price0.00Turnover687.30%IV12.66%PremiumDec 20, 2024Expiry Date0.58Intrinsic Value100Multiplier6DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type0.8318Delta0.1819Gamma2.03Leverage Ratio-0.0307Theta0.0001Rho1.68Eff Leverage0.0005Vega
Regulus Therapeutics Stock Discussion
📊⚡️📊
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vanguard loaded
Regulus Therapeutics Inc., a biopharmaceutical company listed on Nasdaq under the ticker symbol RGLS, has recently announced positive topline results from the third cohort of patients in its Phase 1b Multiple-Ascending Dose (MAD) clinical trial of RGLS8429. This investigational drug is being developed for the treatment of ...
No comment yet